Cribado y abordaje de sarcopenia en personas con diabetes ¿Qué prescribir?

1. Cruz-Jentoft, A. J., Bahat, G., Bauer, J., Boirie, Y., Bruyère, O., Cederholm, T., Cooper, C., Landi, F., Rolland, Y., Sayer, A. A., Schneider, S. M., Sieber, C. C., Topinkova, E., Vandewoude, M., Visser, M., Zamboni, M., Bautmans, I., Baeyens, J.-P., Cesari, M., … Schols, J. (2019). Sarcopenia: revised European consensus on definition and diagnosis. Age and Ageing, 48(1), 16–31. https://doi.org/10.1093/ageing/afy169

2. Gao, Q., Hu, K., Yan, C., Zhao, B., Mei, F., Chen, F., Zhao, L., Shang, Y., Ma, Y., & Ma, B. (2021). Associated Factors of Sarcopenia in Community-Dwelling Older Adults: A Systematic Review and Meta-Analysis. Nutrients, 13(12), 4291. https://doi.org/10.3390/nu13124291

3. Hiromine, Y., Noso, S., Rakugi, H., Sugimoto, K., Takata, Y., Katsuya, T., Fukuda, M., Akasaka, H., Osawa, H., Tabara, Y., & Ikegami, H. (2022). Poor glycemic control rather than types of diabetes is a risk factor for sarcopenia in diabetes mellitus: The MUSCLES‐DM study. Journal of Diabetes Investigation, 13(11), 1881–1888. https://doi.org/10.1111/jdi.13882

4. Johri, N., Vengat, M., Kumar, D., Nagar, P., John, D., Dutta, S., & Mittal, P. (2023). A comprehensive review on the risks assessment and treatment options for Sarcopenia in people with diabetes. Journal of Diabetes & Metabolic Disorders. https://doi.org/10.1007/s40200-023-01262-w

5. Ma, X.-Y., & Chen, F.-Q. (2021). Effects of anti-diabetic drugs on sarcopenia: Best treatment options for elderly patients with type 2 diabetes mellitus and sarcopenia. World Journal of Clinical Cases, 9(33), 10064–10074. https://doi.org/10.12998/wjcc.v9.i33.10064

6. Sasaki, K., & Fukumoto, Y. (2022). Sarcopenia as a comorbidity of cardiovascular disease. Journal of Cardiology, 79(5), 596–604. https://doi.org/10.1016/j.jjcc.2021.10.013

7. Yang, J., Jiang, F., Yang, M., & Chen, Z. (2022). Sarcopenia and nervous system disorders. Journal of Neurology, 269(11), 5787–5797. https://doi.org/10.1007/s00415-022-11268-8

8. Yuan, S., & Larsson, S. C. (2023). Epidemiology of sarcopenia: Prevalence, risk factors, and consequences. Metabolism, 144, 155533. https://doi.org/10.1016/j.metabol.2023.155533

1. Malmstrom TK, Morley JE. SARC-F: a simple questionnaire to rapidly diagnose sarcopenia. J Am Med Dir Assoc 2013;14(8):531-2.

2. Supplementary Table 1 The SARC F scale . Adapted from Malmstrom TK, Morley JE. SARC F: a simple questionnaire to rapidly diagnose sarcopenia. J Am Med Dir Assoc 2013;14(8):5312.

3. Bahat G, Erdoğan T, İlhan B. SARC-F and other screening tests for sarcopenia. Curr Opin Clin Nutr Metab Care. 2022 Jan 1;25(1):37-42. doi: 10.1097/MCO.0000000000000801. PMID: 34861669.

4. Cruz-Jentoft AJ, Bahat G, Bauer J, Boirie Y, Bruyère O, Cederholm T, et al. WRITING GROUP FOR THE EUROPEAN WORKING GROUP ON SARCOPENIA IN OLDER PEOPLE 2 (EWGSOP2), AND THE EXTENDED GROUP FOR EWGSOP2. Sarcopenia: revised European consensus on definition and diagnosis. Age and Ageing 2019; 48: 16–31

5. Chambergo-Michilot D. Gerokomos. 2021;32(1):30-31

6. Coletta G, Phillips SM. An elusive consensus definition of sarcopenia impedes research and clinical treatment: A narrative review. Ageing Res Rev. 2023 Apr;86:101883. doi: 10.1016/j.arr.2023.101883. Epub 2023 Feb 13. PMID: 36792012.

7. Calvo Higuera I, Gomez Carrillo A. Sarcopenia y envejecimiento saludable: reporte de caso. Rev. Nutr. Clin. Metab. [Internet]. 23 de marzo de 2023 [citado 31 de agosto de 2023];6(1). Disponible en: https://revistanutricionclinicametabolismo.org/index.php/nutricionclinicametabolismo/article/view/499

8. Domínguez Chávez CJ, Rosales Garza RB, Aguilar Arámbul SC, Mata Reyes MDC, Monfil Bautista J, Mendoza Catalán G. Association of lifestyle factors with sarcopenia: a systematic review. HS [Internet]. 2022Aug.31 [cited 2023Aug.31];21(3):561-72. Available from: https://revistahorizonte.ujat.mx/index.php/horizonte/article/view/4832 

9. Rojas C, Buckcana A, Benavides G. Sarcopenia: abordaje integral del adulto mayor. Rev Méd Sinerg 2019;4(5):24-34[internet]. Disponible en https://doi.org/10.31434/rms.v4i5.194

10. Erdogan T, Erdogan, T, Catikkas, N M, Oren, M M, Kılıc, C, Karan, M A, & Bahat, G. (2022). Ishii test for screening sarcopenia: performance in community-dwelling older adults. Aging clinical and experimental research, 34(4), 785–791. Available from:  https://doi.org/10.1007/s40520-021-01998-6

11. Montero Errasquin Beatriz. Traducción, adaptación y validación de la versión española del SarQoL: una escala de vida relacionada con la salud específica de sarcopenia. [Tesis doctoral]. Universidad Complutense de Madrid;2018

12. ESPEN - European Society for Clinical Nutrition and Metabolism; 

13. Muscaritoli, M., Anker, S.D., Argiles, J., Aversa, Z., Bauer, J.M., Biolo, G., Boirie, Y., Bosaeus, I., Cederholm, T., Costelli, P., Fearon, K.C., Laviano, A., Maggio, M., Rossi Fanelli, F., Schneider, S.M., Schols, A., Sieber, C.C., 2010. Consensus definition of sarcopenia, cachexia and pre-cachexia: joint document elaborated by Special Interest Groups (SIG) "cachexia-anorexia in chronic wasting diseases" and "nutrition in geriatrics. Clin Nutr 2010 Apr;29(2):154-9. doi: 10.1016/j.clnu.2009.12.004

14. EWGSOP - European Working Group on Sarcopenia in Older People; 

15. Cruz-Jentoft, A.J., Baeyens, J.P., Bauer, J.M., Boirie, Y., Cederholm, T., Landi, F., Martin, F.C., Michel, J.P., Rolland, Y., Schneider, S.M., Topinkova, E., Vandewoude, M., Zamboni, M., European Working Group on Sarcopenia in Older, P, 2010. Sarcopenia: European consensus on definition and diagnosis: report of the European Working Group on sarcopenia in older people. Age Ageing 2010;39(4):412-23

16. IWGS - International Working Group on Sarcopenia

17. WM. C. Chumlea, M. Cesari, W. J. Evans, L. Ferrucci, R. A. Fielding, M. Pahor, S. Studenski, B. Vellas & The Task Force Members. The journal of nutrition, health & aging 2011; 15: 450–455

18. SCWD - Society for Sarcopenia, Cachexia, and Wasting Disorders; 

19. Morley, J.E., Abbatecola, A.M., Argiles, J.M., Baracos, V., Bauer, J., Bhasin, S., Cederholm, T., Coats, A.J., Cummings, S.R., Evans, W.J., Fearon, K., Ferrucci, L., Fielding, R.A., Guralnik, J.M., Harris, T.B., Inui, A., Kalantar-Zadeh, K., Kirwan, B.A., Mantovani, G., Muscaritoli, M., Newman, A.B., Rossi-Fanelli, F., Rosano, G.M., Roubenoff, R., Schambelan, M., Sokol, G.H., Storer, T.W., Vellas, B., von Haehling, S., Yeh, S.S., Anker, S.D., Society on Sarcopenia, C., Wasting Disorders Trialist, W, 2011. Sarcopenia with limited mobility: an international consensus. J. Am. Med. Dir. Assoc. 12, 403–409.

20. AWGS - Asian Working Group for Sarcopenia;
 
21. Chen, L.K., Liu, L.K., Woo, J., Assantachai, P., Auyeung, T.W., Bahyah, K.S., Chou, M.Y., Chen, L.Y., Hsu, P.S., Krairit, O., Lee, J.S., Lee, W.J., Lee, Y., Liang, C.K., Limpawattana, P., Lin, C.S., Peng, L.N., Satake, S., Suzuki, T., Won, C.W., Wu, C.H., Wu, S.N., Zhang, T., Zeng, P., Akishita, M., Arai, H., 2014. Sarcopenia in Asia: consensus report of the Asian Working Group for Sarcopenia. J. Am. Med Dir. Assoc. 15, 95–101. 

22. FNIH - Foundation for the National Institutes of Health; 

23. Studenski, S.A., Peters, K.W., Alley, D.E., Cawthon, P.M., McLean, R.R., Harris, T.B., Ferrucci, L., Guralnik, J.M., Fragala, M.S., Kenny, A.M., Kiel, D.P., Kritchevsky, S.B., Shardell, M.D., Dam, T.T., Vassileva, M.T., 2014. The FNIH sarcopenia project: rationale, study description, conference recommendations, and final estimates. J. Gerontol. A Biol. Sci. Med. Sci.2014;  69, 547–558.

24. SDOC - Sarcopenia Definitions and Outcomes Consortium.

25. Bhasin, S., Travison, T.G., Manini, T.M., Patel, S., Pencina, K.M., Fielding, R.A., Magaziner, J.M., Newman, A.B., Kiel, D.P., Cooper, C., Guralnik, J.M., Cauley, J.A., Arai, H., Clark, B.C., Landi, F., Schaap, L.A., Pereira, S.L., Rooks, D., Woo, J., Woodhouse, L.J., Binder, E., Brown, T., Shardell, M., Xue, Q.L., D’Agostino Sr., R.B., Orwig, D., Gorsicki, G., Correa-De-Araujo, R., Cawthon, P.M., 2020. Sarcopenia definition: the position statements of the sarcopenia definition and outcomes consortium. J. Am. Geriatr. Soc. 2020; 68, 1410–1418.

26. Parra-Rodríguez L. et al. Cross-Cultural Adaptation and Validation of the Spanish-Language Version of the SARC-F to Assess Sarcopenia in Mexican Community-Dwelling Older Adults. JAMDA 17 (2016) 1142e1146.

27. Roberts HC, et al. A review of the measurement of grip strength in clinical and epidemiological studies: towards a standardised approach. Age and Ageing 2011; 40: 423–429

28. Cuestionario SarQol. Calidad de vida en la sarcopenia. Questionnaire_SarQoL_ES-2017-06_0.pdf. Fecha consulta 09.04.2025.

1. García-Almeida JM et al. Abordaje de la desnutrición en pacientes hospitalizados con diabetes/hiperglucemia y sarcopenia. Malnutrition management of hospitalized patients with diabetes/hyperglycemia and sarcopenia. Nutr Hosp 2022;39(N.º Extra. 4):15-22.

2. Deutza NE et al. Protein intake and exercise for optimal muscle function with aging: Recommendations from the ESPEN Expert Group. Clin Nutr. 2014 December; 33(6): 929–936. 

3. Recomendaciones dietéticas saludables y sostenibles complementadas con recomendaciones de actividad física para la población española. Recomendaciones dietéticas saludables y sostenibles complementadas con recomendaciones de actividad física para la población española | Ministerio de Derechos Sociales, Consumo y Agenda 2030.  Fecha consulta 09.04.2025.

4. Liu S, Zhang L, Li S. Advances in nutritional supplementation for sarcopenia management. Front Nutr. 2023 Jul 10;10:1189522. doi: 10.3389/fnut.2023.1189522

5. Volkert, D.; Beck, A.M.; Cederholm, T.; Cruz-Jentoft, A.; Goisser, S.; Hooper, L.; Kiesswetter, E.; Maggio, M.; Raynaud-Simon, A.; Sieber, C.C.; et al. ESPEN guideline on clinical nutrition and hydration in geriatrics. Clin. Nutr. 2019, 38, 10–47
 
6. Deutz NE, Bauer JM, Barazzoni R, Biolo G, Boirie Y, Bosy-Westphal A, Cederholm T, Cruz-Jentoft A, Krznariç Z, Nair KS, et al. Protein intake and exercise for optimal muscle function with aging: recommendations from the ESPEN Expert Group. Clin Nutr. 2014;33:929–936. doi: 10.1016/j.clnu.2014.04.007

7. Kim D, Kim J. Effects of β-hydroxy-β-methylbutyrate supplementation on recovery from exercise-induced muscle damage: a mini-review. Phys Act Nutr. (2022) 26:41–5. doi: 10.20463/pan.2022.0023

8. Dawson-Hughes B. Vitamin D and muscle function. J Steroid Biochem Mol Biol. (2017) 173:313–6. doi: 10.1016/j.jsbmb.2017.03.018

1. David E. Barajas-Galindo, Elena González Arnáiz, Pablo Ferrero Vicente, María D. Ballesteros-Pomar. Efectos del ejercicio físico en el anciano con sarcopenia. Una revisión sistemática. Endocrinología, Diabetes y Nutrición 2021; 68: 159-169

2. M Gargallo et al. Área de Trabajo de Diabetes Mellitus de la SEEN. Guía RECORD SEEN (actualización 2021). Recomendaciones clínicas para la práctica de deporte en personas con Diabetes Mellitus https://www.seen.es/portal/informacion-sobre-enfermedades/diabetes/guia-record-diabetes-mellitus-2021

3. Mikel Izquierdo. Prescripción de ejercicio físico. El programa Vivifrail como modelo. Nutr Hosp 2019;36 (N.º Extra. 2):50-56

1. Zhang S et al.  Effect of sodium-glucose transporter 2 inhibitors on sarcopenia in patients with type 2 diabetes mellitus: a systematic review and meta-analysis. Endocrinol. 14:1203666. doi: 10.3389/fendo.2023.1203666.

2. J. Girbés Borrás et al. Consenso sobre tratamiento con insulina en la diabetes tipo 2. Endocrinol Diabetes Nutr. 2018;65(S1):1-8.

3. Pan R, Zet al. Effect of SGLT-2 inhibitors on body composition in patients with type 2 diabetes mellitus: A meta-analysis of randomized controlled trials. PLoS ONE 17(12): e0279889. https://doi.org/10.1371/journal.pone.0279889.

4. Massimino E, Izzo A, Riccardi G, Della Pepa G. The Impact of Glucose-Lowering Drugs on Sarcopenia in Type 2 Diabetes: Current Evidence and Underlying Mechanisms. Cells. 2021;10(8):1958. Published 2021 Aug 1. doi:10.3390/cells10081958

5. Ferrari, U.; Then, C.; Rottenkolber,M.; Selte, C.; Seissler, J.; Conzade, R.; Linkohr, B.; Peters, A.; Drey,M.; Thorand, B. Longitudinal association of type 2 diabetes and insulin therapy with muscle parameters in the KORA-Age study. Acta. Diabetol. 2020, 57, 1057–1063.

6. Bouchi, R.; Fukuda, T.; Takeuchi, T.; Nakano, Y.;Murakami,M.;Minami, I.; Izumiyama, H.; Hashimoto, K.; Yoshimoto, T.; Ogawa, Y. Insulin Treatment Attenuates Decline of Muscle Mass in Japanese Patients with Type 2 Diabetes. Calcif. Tissue Int. 2017, 101, 1–8.

7. Liu ZJ, Zhu CF. Causal relationship between insulin resistance and sarcopenia. Diabetol Metab Syndr. 2023;15(1):46. Published 2023 Mar 15. doi:10.1186/s13098-023-01022-z

8. Sanz-Cánovas J, López-Sampalo A, Cobos-Palacios L, et al. Management of Type 2 Diabetes Mellitus in Elderly Patients with Frailty and/or Sarcopenia. Int J Environ Res Public Health. 2022;19(14):8677. Published 2022 Jul 16. doi:10.3390/ijerph19148677

9. Laksmi, P.W.; Setiati, S.; Tamin, T.Z.; Soewondo, P.; Rochmah,W.; Nafrialdi, N.; Prihartono, J. Effect of Metformin on Handgrip Strength, Gait Speed, Myostatin Serum Level, and Health-related Quality of Life: A Double Blind Randomized Controlled Trial among Non-diabetic Pre-frail Elderly Patients. Acta. Med. Indones. 2017, 49, 118–127.

10. Tsurutani, Y.; Nakai, K.; Inoue, K.; Azuma, K.; Mukai, S.; Maruyama, S.; Iizuka, T.; Matsuzawa, Y.; Saito, J.; Omura, M.; et al. Comparative study of the effects of ipragliflozin and sitagliptin on multiple metabolic variables in Japanese patients with type 2 diabetes: A multicentre, randomized, prospective, open-label, active-controlled study. Diabetes Obes. Metab. 2018, 20, 2675–2679

11. Yajima, T.; Yajima, K.; Takahashi, H.; Yasuda, K. The effect of dulaglutide on body composition in type 2 diabetes mellitus patients on hemodialysis. J. Diabetes Complications 2018, 32, 759–763

12. Hong, J.Y.; Park, K.Y.; Kim, B.J.; Hwang, W.M.; Kim, D.H.; Lim, D.M. Effects of Short-Term Exenatide Treatment on Regional Fat Distribution, Glycated Hemoglobin Levels, and Aortic PulseWave Velocity of Obese Type 2 Diabetes Mellitus Patients. Endocrinol. Metab. 2016, 31, 80–85. 

13. Mele, A.; Calzolaro, S.; Cannone, G.; Cetrone,M.; Conte, D.; Tricarico, D. Database search of spontaneous reports and pharmacological investigations on the sulfonylureas and glinides-induced atrophy in skeletal muscle. Pharmacol. Res. Perspect. 2014, 2, e00028

14. Yamakage, H.; Tanaka, M.; Inoue, T.; Odori, S.; Kusakabe, T.; Satoh-Asahara, N. Effects of dapagliflozin on the serum levels of fibroblast growth factor 21 and myokines and muscle mass in Japanese patients with type 2 diabetes: A randomized, controlled trial. J. Diabetes Investig. 2020, 11, 653–661.

15. Matsuba, R.; Matsuba, I.; Shimokawa, M.; Nagai, Y.; Tanaka, Y. Tofogliflozin decreases body fat mass and improves peripheral insulin resistance. Diabetes Obes. Metab. 2018, 20, 1311–1315

16. Yokota, T.; Kinugawa, S.; Hirabayashi, K.; Suga, T.; Takada, S.; Omokawa, M.; Kadoguchi, T.; Takahashi, M.; Fukushima, A.; Matsushima, S.; et al. Pioglitazone improves whole-body aerobic capacity and skeletal muscle energy metabolism in patients with metabolic syndrome. J. Diabetes Investig. 2017, 8, 535–541.

17. Shea, M.K.; Nicklas, B.J.; Marsh, A.P.; Houston, D.K.; Miller, G.D.; Isom, S.; Miller, M.E.; Carr, J.J.; Lyles, M.F.; Harris, T.B.; et al. The effect of pioglitazone and resistance training on body composition in older men and women undergoing hypocaloric weight loss. Obesity 2011, 19, 1636–1646

18. A Ma XY, Chen FQ. Effects of anti-diabetic drugs on sarcopenia: Best treatment options for elderly patients with type 2 diabetes mellitus and sarcopenia. World J Clin Cases. 2021 Nov 26;9(33)

19. B Zhang X, Zhao Y, Chen S, Shao H. Anti-diabetic drugs and sarcopenia: emerging links, mechanistic insights, and clinical implications. J Cachexia Sarcopenia Muscle. 2021 Dec;12(6):1368-1379.

20. Reyes-García R, Moreno-Pérez , Tejera-Pérez C, Fernández-García D, Bellido-Castañeda V, de la Torre Casares ML, Rozas-Moreno P, Fernández-García JC, Marco Martínez A, Escalada-San Martín J, Gargallo-Fernández M, Botana-López M, López-Fernández J, González-Clemente JM, Jódar-Gimeno E, Mezquita-Raya P; en representación del Grupo de trabajo de Diabetes-SEEN. Document on a comprehensive approach to type 2 diabetes mellitus. Endocrinol Diabetes Nutr. 2019 ;66(7):443-458. 

21. Zhang S, Qi Z, Wang Y, Song D and Zhu D (2023) Effect of sodium-glucose transporter 2 inhibitors on sarcopenia in patients with type 2 diabetes mellitus: a systematic review and meta-analysis. Front. Endocrinol. 14:1203666. doi: 10.3389/fendo.2023.1203666.